Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004199778> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2004199778 endingPage "10" @default.
- W2004199778 startingPage "3" @default.
- W2004199778 abstract "d-(−)4-(3-phosphonopropyl)piperazine-2-carboxylic acid (D-CPP) and its unsaturated analogue (d(−)(E)-4-(3-phosphonoprop-2-enyl) piperazine-2-carboxylic acid (D-CPPene) have been administered to DBA/2 mice (intracerebroventricularly, i.c.v., intraperitoneally, i.p., and orally, p.o.) and to photosensitive baboons, Papio papio (intravenously, i.v., and orally), and their effects on reflexly induced epileptic responses assessed. In DBA/2 mice the clonic phase of the seizure response to sound is suppressed by D-CPP with an ED50 of 5.5 μg/mouse, i.c.v.; 0.69 mg (2.75 μmol)/kg i.p. and 16.6 mg (65.8 μmol)/kg p.o. compared with, for D-CPPene, 2.2 μg/mouse i.c.v., 0.41 mg (1.54 μmol)/kg i.p. and 10.8 mg (40.2 μmol)/kg, p.o. In Papio papio myoclonic responses to strobostopic stimulation are suppressed 24 and 48 h after D-CPP 32 mg (127 μmol)/kg p.o. Administration of D-CPPene 8–16 mg (30–60 μmol)/kg i.v. produces protection against myoclonic responses after 1–2 h, lasting for 48 h. Oral administration of D-CPPene 32–64 mg (119–239 μmol)/kg produces protection beginning after 4 h and sustained for 48 h. Measurements of plasma D-CPPene concentration show clearance after i.v. injection and a low plasma concentration 1.5–5 h after oral administration. The prolonged anticonvulsant action of D-CPP and D-CPPene following oral administration suggests that these compounds merit evaluation as antiepileptic therapy in man." @default.
- W2004199778 created "2016-06-24" @default.
- W2004199778 creator A5012704137 @default.
- W2004199778 creator A5034388856 @default.
- W2004199778 creator A5036778920 @default.
- W2004199778 creator A5047336117 @default.
- W2004199778 creator A5077329743 @default.
- W2004199778 date "1990-09-01" @default.
- W2004199778 modified "2023-09-27" @default.
- W2004199778 title "Anticonvulsant activity of the NMDA antagonists, d(−)4-(3-phosphonopropyl)piperazine-2-carboxylic acid (D-CPP) and d(−)(E)-4-(3-phosphonoprop-2-enyl) piperazine-2-carboxylic acid (D-CPPene) in a rodent and a primate model of reflex epilepsy" @default.
- W2004199778 cites W1968956259 @default.
- W2004199778 cites W1982549830 @default.
- W2004199778 cites W2025801062 @default.
- W2004199778 cites W2079479998 @default.
- W2004199778 cites W2082638704 @default.
- W2004199778 cites W2083674587 @default.
- W2004199778 cites W2135723161 @default.
- W2004199778 doi "https://doi.org/10.1016/0920-1211(90)90049-2" @default.
- W2004199778 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2292244" @default.
- W2004199778 hasPublicationYear "1990" @default.
- W2004199778 type Work @default.
- W2004199778 sameAs 2004199778 @default.
- W2004199778 citedByCount "76" @default.
- W2004199778 countsByYear W20041997782013 @default.
- W2004199778 countsByYear W20041997782014 @default.
- W2004199778 countsByYear W20041997782015 @default.
- W2004199778 countsByYear W20041997782016 @default.
- W2004199778 countsByYear W20041997782021 @default.
- W2004199778 countsByYear W20041997782022 @default.
- W2004199778 crossrefType "journal-article" @default.
- W2004199778 hasAuthorship W2004199778A5012704137 @default.
- W2004199778 hasAuthorship W2004199778A5034388856 @default.
- W2004199778 hasAuthorship W2004199778A5036778920 @default.
- W2004199778 hasAuthorship W2004199778A5047336117 @default.
- W2004199778 hasAuthorship W2004199778A5077329743 @default.
- W2004199778 hasConcept C118552586 @default.
- W2004199778 hasConcept C134018914 @default.
- W2004199778 hasConcept C170493617 @default.
- W2004199778 hasConcept C185592680 @default.
- W2004199778 hasConcept C2775858608 @default.
- W2004199778 hasConcept C2776201271 @default.
- W2004199778 hasConcept C2777056448 @default.
- W2004199778 hasConcept C2778186239 @default.
- W2004199778 hasConcept C2779074116 @default.
- W2004199778 hasConcept C42533223 @default.
- W2004199778 hasConcept C55493867 @default.
- W2004199778 hasConcept C71240020 @default.
- W2004199778 hasConcept C71924100 @default.
- W2004199778 hasConcept C98274493 @default.
- W2004199778 hasConceptScore W2004199778C118552586 @default.
- W2004199778 hasConceptScore W2004199778C134018914 @default.
- W2004199778 hasConceptScore W2004199778C170493617 @default.
- W2004199778 hasConceptScore W2004199778C185592680 @default.
- W2004199778 hasConceptScore W2004199778C2775858608 @default.
- W2004199778 hasConceptScore W2004199778C2776201271 @default.
- W2004199778 hasConceptScore W2004199778C2777056448 @default.
- W2004199778 hasConceptScore W2004199778C2778186239 @default.
- W2004199778 hasConceptScore W2004199778C2779074116 @default.
- W2004199778 hasConceptScore W2004199778C42533223 @default.
- W2004199778 hasConceptScore W2004199778C55493867 @default.
- W2004199778 hasConceptScore W2004199778C71240020 @default.
- W2004199778 hasConceptScore W2004199778C71924100 @default.
- W2004199778 hasConceptScore W2004199778C98274493 @default.
- W2004199778 hasIssue "1" @default.
- W2004199778 hasLocation W20041997781 @default.
- W2004199778 hasLocation W20041997782 @default.
- W2004199778 hasOpenAccess W2004199778 @default.
- W2004199778 hasPrimaryLocation W20041997781 @default.
- W2004199778 hasRelatedWork W1944089652 @default.
- W2004199778 hasRelatedWork W2004199778 @default.
- W2004199778 hasRelatedWork W2005179275 @default.
- W2004199778 hasRelatedWork W2005905138 @default.
- W2004199778 hasRelatedWork W2007905335 @default.
- W2004199778 hasRelatedWork W2012490361 @default.
- W2004199778 hasRelatedWork W2026501837 @default.
- W2004199778 hasRelatedWork W2151767830 @default.
- W2004199778 hasRelatedWork W2461080865 @default.
- W2004199778 hasRelatedWork W2748952813 @default.
- W2004199778 hasVolume "7" @default.
- W2004199778 isParatext "false" @default.
- W2004199778 isRetracted "false" @default.
- W2004199778 magId "2004199778" @default.
- W2004199778 workType "article" @default.